Pinney & Scofield’s CRISPR Therapeutics CRSP Stock Holding History

Pinney & Scofield’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.09K	Hold	75	–	–	﹤0.01%	200
2026 Q1	$3.57K	Buy	+75	New	+$3.96K	﹤0.01%	209

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pinney & Scofield's CRSP Position: Q2 2026 in Review

Pinney & Scofield held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 75 shares worth $4.09K. The position accounts for ﹤0.01% of the portfolio, ranked #200.

Pinney & Scofield first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Pinney & Scofield held 75 shares of CRISPR Therapeutics worth $4.09K as of Q2 2026.
Pinney & Scofield left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Pinney & Scofield's portfolio in Q2 2026, its #200 holding.
Pinney & Scofield first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pinney & Scofield's 13F filing for Q2 2026, filed 7 Aug 2026.